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Abstract
Cutaneous vasculitis is a clinical entity with a broad
differential diagnosis, including an adverse drug reaction.
It is defined as inflammation of skin blood vessel walls. During
a 7-year-period, we observed three patients who developed
isolated cutaneous vasculitis during antibiotic therapy of
bacterial infection. All were treated with a fluoroquinolone
(ciprofloxacin or levofloxacin) combined with rifampin (two
cases) or flucloxacillin (three cases), respectively. In all three
cases the lesions gradually resolved after treatment with the
inciting fluoroquinolone had been stopped. In one patient,
leukocytoclastic small-vessel vasculitis was histologically
confirmed. Fluoroquinolone-associated cutaneous vasculitis
consists of an isolated self-limiting disorder that is part of a
systemic vasculitis, or even life-threatening disease. Clinicians
should be aware of this serious adverse event because any
continuation of treatment may be fatal.
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Introduction
Cutaneous vasculitis is defined as inflammation of the skin
blood vessels [1]. Histologically, the most common cuta-
neous manifestation of this clinical entity is leukocyto-
clastic vasculitis, which preferentially affects small vessels
of the lower extremities and is clinically characterized
by palpable purpuric lesions, sometimes with slight
focal necrosis and ulceration [2]. No obvious triggering
event has been detected to date in primary vasculitis; in
contrast, the etiology of secondary vasculitis is known [3]
and includes inflammatory reaction to drugs, infection,
neoplasia, or autoimmune disease. Isolated cutaneous
leukocytoclastic vasculitis is often associated with a
drug hypersensitivity response, and the clinical symptoms
improve when the drug is stopped [4]. Drugs that have
been implicated in the hypersensitivity response include
penicillins, aminopenicillins, sulfonamide-based drugs
(including antibacterial sulfonamides as well as most
loop- and thiazide-type diuretics), quinolones, allopurinol,
and propylthiouracil [1]. Hypersensitivity vasculitis is
commonly associated with circulating immune com-
plexes. The drugs act as haptens, stimulating an immune
response, followed by the formation of circulating immune
complexes that are deposited in postcapillary venules and
arterioles, inducing inflammation [1].
Case Reports
Case 1
A 68-year-old man with a hematogenous total knee arthro-
plasty-associated infection due to Staphylococcus aureus was
treated with debridement and iv-flucloxacillin. Two weeks later,
antibiotics were switched to oral ciprofloxacin plus rifampin.
After 7 days, an erythematous palpable purpuric rash appeared
on both legs. This exanthema was interpreted as a manifesta-
tion of an uncontrolled infection. One week later, a dermatol-
ogist, who was asked to consult with the patient due to
progressing necrotic skin lesions, clinically diagnosed drug-in-
duced vasculitis and stopped treatment with both antibiotics.
Following continuation of the treatment with flucloxacillin
alone, and later with fusidic acid plus rifampin, all lesions
gradually healed.
Case 2
A 74-year-old man with a vascular prosthesis-associated infection
due to S. aureus was treated with iv-flucloxacillin. Two weeks
later, ciprofloxacin was added because of nosocomial urinary
tract infection due to Klebsiella pneumoniae. After 8 days, hem-
orrhagic lesions and palpable purpura appeared (Figure 1). This
exanthema was diagnosed as Janeway lesions, and endocarditis
was considered as differential diagnosis. However, the Infectious
Disease consultant diagnosed drug hypersensitivity based on the
presence of only two minor Duke criteria and because the con-
sultant had been primed by the former case. Therefore, cipro-
floxacin was immediately stopped, and the lesions gradually
disappeared within 1 week despite continuous flucloxacillin
therapy.
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Case 3
A 65-year-old man suffered from a cervical hematogenous
epidural abscess after iv-catheter-associated sepsis due to S.
aureus. After neurosurgical de´bridement, he was treated with
iv-flucloxacillin for 2 weeks and then switched to oral levo-
floxacin plus rifampin. Three days later, palpable purpura
appeared. Leukocytoclastic small-vessel vasculitis was histo-
logically confirmed by means of a punch biopsy (Figure 2).
After the levofloxacin plus rifampicin drug therapy was stopped
and the patient switched back to flucloxacillin alone, the skin
lesions rapidly disappeared. Rifampicin was later reintroduced
together with fusidic acid because no case of cutaneous vasculitis
due to rifampin has been described to date. After an overall
drug treatment of 7 weeks, therapy was stopped without reap-
pearance of skin vasculitis.
Discussion
All three patients described here had clinically and/or
histologically confirmed cutaneous small-vessel vasculitis
[5] without antineutrophil cytoplasmatic antibodies
(ANCA). None of the patients showed evidence of glo-
merulonephritis or other systemic involvement. In each of
these patients, the appearance and disappearance strictly
correlated with ciprofloxacin or levofloxacin therapy.
Drug-induced immune complex vasculitis, also de-
noted hypersensitivity vasculitis, is a small-vessel vasculi-
tis involving postcapillary venules and arterioles. It is a
common clinical feature of a severe cutaneous reaction
induced by drugs [2] and has the clinical hallmarks of
palpable purpura and/or petechiae. Diagnosis must be
considered in the case of typical clinical findings and a
history of a new therapy with a drug known to potentially
cause hypersensitivity vasculitis. Skin biopsy shows a
leukocytoclastic vasculitis (Figure 2), i.e., intense infiltra-
tion of inflammatory cells, primarily polymorphonuclear
leukocytes, and fragments of degenerated leukocyte nu-
clei (‘‘nuclear dust’’). The immune complexes are depos-
ited in tissue, thereby causing vasculitis [1] through the
narrowing and occlusion of the vessel lumen and by
necrosis of the wall. Drugs implicated in hypersensitivity
vasculitis include penicillins, aminopenicillins, sulfon-
amide-based drugs (including antibacterial sulfonamides
Figure 1. Case number 2. Acute appearance of palpable purpura
after 3 weeks of therapy of S. aureus sepsis with flucloxacillin, and
after 1 week treatment of an urinary tract infection with
ciprofloxacin.
Figure 2. Case number 3. Section
from a punch biopsy of skin lesions
(palpable purpura) which appeared
3 days after the antibiotic therapy of
the patient had been switched from
flucloxacillin to levofloxacin plus
rifampicin (hematoxylin + eosin
stain; magnification ·200 left, ·400
right). a) Fibrinoid type necrosis
(arrow), b) Fragmented neutrophils
(arrow) (Courtesy of Prof. G.
Cathomas, Kantonales Institut für
Pathologie, Liestal).
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as well as most loop- and thiazide-type diuretics), quino-
lones, allopurinol, and propylthiouracil [2]. Some drugs
act as haptens, conjugating to serum proteins and medi-
ating the formation of immune complexes (e.g., penicil-
lins). Other drugs, such as foreign proteins, including
streptokinase, cause cutaneous vasculitis by the formation
of immune complexes [6]. In addition, some drugs appear
to cause vasculitis by inducing ANCA (e.g., propylthio-
uracil, anti-tumor-necrosis factor-a), although a cause-
and-effect relation has not been proven [7]. Vasculitis
usually starts 7–10 days after antigen exposure, by which
time sufficient immune complexes have been produced
[1]. However, the latent period may be as short as 2–7
days (case no. 3) with a secondary antigen exposure, or
longer than 2 weeks with a long-acting drug, such as
benzathine penicillin [8]. The fact that a patient has been
receiving a drug for an extended time does not exclude
that drug from consideration because drug hypersensitiv-
ity is not time- or dose-dependent [9]. Discontinuation of
the inciting drug should result in the prompt resolution of
signs within days to a few weeks.
A special form of non-ANCA vasculitis is Henoch–
Scho¨nlein purpura. It is clinically characterized by pur-
pura, abdominal pain (gut vasculitis), nephritis (renal
vasculitis), and arthralgia/arthritis (immune complex
synovitis). Immune histochemistry shows vascular depo-
sition of immunoglobulin (Ig)A-dominant immune com-
plexes in small vessels. It is most frequent in childhood,
with a peak incidence at age 5 years. This disease often
begins after an upper respiratory tract infection, and it is
not correlated with drug therapy [10].
Cutaneous vasculitis has also been observed during
infections, such as endocarditis, bacteremia due to men-
ingococci and gonococci, and chronic hepatitis C as well as
other chronic infections. The mechanism of infection-
associated vasculitis is also vascular inflammation due to
the formation of local immune complexes. Although our
three patients had severe S. aureus infection, it was not the
cause of their cutaneous vasculitis because of the strict
correlation between starting and stopping fluoroquinolone
therapy and the manifestation and (gradual) disappear-
ance of symptoms, respectively.
No association with ANCA has been described in
quinolone-induced vasculitis, unlike in Wegener’s granu-
lomatosis, Churg–Strauss syndrome, or microscopic poly-
angiitis.
Several cases of cutaneous and/or renal vasculitis due
to ciprofloxacin, ofloxacin, and levofloxacin drug therapy
have been reported [11–20]. In the published Swiss drug
information sheet (Swiss Drug Compendium, Documed,
Basel), cutaneous vasculitis is mentioned as adverse
events of ciprofloxacin and ofloxacin, but not of levo-
floxacin. Whether it is a class effect of fluoroquinolones
is unknown. According to Pubmed, with the exception
of the three patients reported here, there have been no
cases of cutaneous vasculitis as an adverse event to other
fluoroquinolones. In view of our three cases within 7 years
(13,700 hospitalized patients/year), cutaneous vasculitis
associated with ciprofloxacin, ofloxacin, or levofloxacin is
not a very rare event. Skin lesions may be misinterpreted
as a sign of infection. Therefore, each clinician should be
aware of quinolone-associated hypersensitivity vasculitis,
since any continuation of therapy may be fatal [15].
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